Latitude versus Curex, from Curex

When its map and calendar fit your life. That means a clinic within sustainable reach — Latitude operates roughly a dozen locations across the Bay Area, Southern California, and the New York metro — a family that can hold frequent supervised in-person up-dosing visits through a 6–12 month active phase, and funding for a program fee patients report at $4,000–$5,000+ that Latitude's own FAQ describes as a non-covered service. In exchange you get the fastest supervised route to maintenance (published average ~8.4 months), oral food challenges that can remove false-positive allergy labels before anyone treats them, and in-network billing for visits and diagnostics with major insurers. For a coastal-metro family that wants supervised speed, it is a strong choice.

When the at-home model is the one your life can hold: outside the coastal metros, a family that moves or travels, shift work, adults, a child in sport, or anyone a harsher protocol would not survive. Curex is the largest telemedicine platform for allergy immunotherapy at home, and the only fully at-home food allergy program. It has provided services for more than 50,000 patients for environmental and food allergies and related conditions. Most of the country lives outside Latitude's three metros — 15 states plus DC list no OIT clinic at all — and time burden is the #1 documented reason families decline clinic immunotherapy. Testing runs through local labs or self-collection, doctors see you by video or text, and a licensed compounding pharmacy ships the drops, on a $199-a-month plan with environmental allergy plans from $79. Anaphylaxis history or severe, poorly controlled asthma routes to in-person assessment first, regardless of provider.

Same category, different tool. Both are allergy immunotherapy — the only disease-modifying treatment for allergies, in clinical use for over 100 years — but the modality and dose logic differ. Latitude's programs center on swallowing escalating doses of the allergen under clinical supervision. Food SLIT uses much smaller, precise doses held under the tongue; the effect comes through the sublingual mucosa, and swallowed, the same tiny dose would be ineffective. One head-to-head trial in peanut-allergic children found OIT raised reaction thresholds about 141-fold at 12 months versus about 22-fold for SLIT — but OIT also produced significantly more adverse reactions and more withdrawals. That single trial is the whole trade in miniature: faster and stronger versus gentler and easier to stay on.

Latitude does not publish its OIT program fee. Its FAQ says diagnostics and visits are typically covered in-network — it lists Aetna, Anthem, Blue Shield, Cigna, UnitedHealthcare and others across its three regions — but calls the one-time OIT program fee a non-covered service, with payment plans and FSA/HSA eligibility. Patients report the fee at more than $4,000 in the Bay Area and over $5,000 in New York, so treat it as a $4,000–$5,000+ range by region and time. In-person food allergy programs in general can exceed $10,000 per year. Curex's food allergy plan is $199 a month, with environmental allergy plans from $79 a month, and patients can generally save more than $10,000 over a course of treatment versus in-person programs. Both of us owe you the all-in figure in writing before you commit — ask both.

Latitude publishes 6–12 months of active treatment to reach maintenance, with an average around 8.4 months — genuinely fast, and a direct product of supervised, more aggressive dosing. Maintenance dosing then continues long-term; Latitude offers lifelong maintenance care. Curex's food SLIT is more gentle and generally a bit slower, and a full immunotherapy course typically runs 3–5 years, though many patients notice improvement in the first months. Neither program ends at a finish line where treatment stops mattering: desensitization is maintained, not banked. The honest question isn't which is faster on paper but which schedule your family can actually sustain — clinic frequent in-person visits for most of a year, or a daily dose at home.

Latitude primarily treats children, but adults have been accepted: one 36-year-old peanut-allergic patient reported being taken on "although they stated they don't normally treat adults," with a peanut component IgE of 2.0 or greater cited as the threshold, and reaching maintenance in the standard 6–12 months. Curex treats adults as a matter of course — the daily-rules burden of OIT (no strenuous exercise or hot showers for roughly 2–3 hours after dosing, alcohol caution) tends to collide hardest with adult routines, which is part of why gentler sublingual dosing suits many adult patients. Either way, candidacy is clinical: an evaluation decides whether you may be a candidate, and anaphylaxis history or severe asthma means in-person assessment first.

Read it with its label attached: "98% of patients under 4 achieved desensitization" and "94% of all ages" are sourced by Latitude to internal data, 2026 — earlier materials cited 92% within one year and 97% for under-4s. Its safety figure has stronger provenance: an AAAAI 2025 presentation with Weill Cornell found about 5% of doses among 1,000+ OIT patients caused any reaction, the overwhelming majority mild. Latitude's third-party record is clean — no BBB complaints, 276 strongly positive Zocdoc reviews, and no skepticism cluster of the kind that surrounds some competitors. Apply the same scrutiny to Curex. Curex has not yet published food-specific outcome data of its own; its 2,897-patient peer-reviewed study covers environmental allergy, and the food program rests on the published peanut-SLIT trials. How we handle our own record is at [is Curex legit](/learn/is-curex-legit).

No — and since 31 July 2026, nothing in this market is. Palforzia, the only FDA-approved food oral immunotherapy product, was withdrawn from the US market that day as a commercial decision, so every food immunotherapy program — Latitude's clinic protocols and Curex's at-home program alike — is off-label. Off-label is not the same as unsafe: it describes clinician-directed use, and Curex's prescriptions are compounded from FDA-approved allergenic extracts (the extracts hold the approval, not the drops). The only FDA-approved food allergy medication now is Xolair (approved February 2024, ages 1+), which reduces reaction severity on accidental exposure but does not desensitize — avoidance continues. The full landscape is mapped at [food allergy treatment options](/learn/food-allergy-treatment-options).

As the third leader, and as the origin of the at-home route. Allergy Associates of La Crosse in Onalaska, Wisconsin has treated food and environmental allergy with sublingual drops since 1970, has treated more than 275,000 patients by its own account, and wrote the La Crosse Method protocol. So sublingual treatment has two ways in: an in-person first visit in Onalaska ($750–850 typical, $1,000–1,400 complex; drops about $2.20 a day; rechecks every 3–6 months in person or virtual; 3–5 years), or the whole course at home through Curex. La Crosse is the named in-person option for a history of anaphylaxis or uncontrolled asthma.